Syncom Formulations (SYNCOMF) | Financial Analysis & Statements
Syncom Formulations (India) Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2025Income Metrics
Revenue
1.2B
Gross Profit
509.6M
41.87%
Operating Income
170.5M
14.01%
Net Income
166.0M
13.64%
EPS (Diluted)
₹0.18
Balance Sheet Metrics
Total Assets
4.1B
Total Liabilities
711.2M
Shareholders Equity
3.4B
Debt to Equity
0.21
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2025
Syncom Formulations Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.6B | 2.6B | 2.2B | 2.2B | 2.4B |
| Cost of Goods Sold | 3.2B | 1.7B | 1.5B | 1.5B | 1.7B |
| Gross Profit | 1.4B | 942.4M | 726.4M | 709.7M | 722.4M |
| Gross Margin % | 31.0% | 36.4% | 32.6% | 32.6% | 30.2% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 376.1M | 294.6M | 250.3M | 274.5M | 177.2M |
| Other Operating Expenses | 44.3M | 34.2M | 27.6M | 23.4M | 16.6M |
| Total Operating Expenses | 420.4M | 328.7M | 277.9M | 297.9M | 193.7M |
| Operating Income | 541.5M | 251.7M | 164.5M | 172.7M | 350.1M |
| Operating Margin % | 11.8% | 9.7% | 7.4% | 7.9% | 14.6% |
| Non-Operating Items | |||||
| Interest Income | 17.1M | 55.2M | 47.2M | 39.3M | 13.5M |
| Interest Expense | 7.1M | 43.6M | 31.9M | 18.3M | 1.9M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 655.1M | 339.5M | 265.7M | 261.8M | 407.0M |
| Income Tax | 160.8M | 86.4M | 65.0M | 63.9M | 115.3M |
| Effective Tax Rate % | 24.5% | 25.4% | 24.5% | 24.4% | 28.3% |
| Net Income | 494.3M | 253.1M | 200.7M | 197.9M | 291.7M |
| Net Margin % | 10.8% | 9.8% | 9.0% | 9.1% | 12.2% |
| Key Metrics | |||||
| EBITDA | 710.0M | 423.0M | 341.2M | 319.1M | 448.0M |
| EPS (Basic) | ₹0.53 | ₹0.27 | ₹0.22 | ₹0.26 | ₹0.37 |
| EPS (Diluted) | ₹0.53 | ₹0.27 | ₹0.22 | ₹0.24 | ₹0.36 |
| Basic Shares Outstanding | 940000000 | 940000000 | 928500000 | 816850000 | 780754000 |
| Diluted Shares Outstanding | 940000000 | 940000000 | 928500000 | 816850000 | 780754000 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Syncom Formulations Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 6.6M | 632.9M | 7.6M | 2.2M | 26.4M |
| Short-term Investments | 892.2M | 681.8M | 700.2M | 400.3M | 713.4M |
| Accounts Receivable | 1.1B | 1.0B | 755.1M | 675.5M | 748.2M |
| Inventory | 413.3M | 210.8M | 212.0M | 195.1M | 225.6M |
| Other Current Assets | 377.0K | 377.0K | 377.0K | 377.0K | 377.0K |
| Total Current Assets | 2.7B | 2.7B | 1.8B | 1.4B | 1.9B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 92.5M | 92.1M | 60.2M | 58.3M | 57.1M |
| Goodwill | 472.0K | 1.1M | 1.8M | 990.0K | 1.2M |
| Intangible Assets | 472.0K | 1.1M | 1.8M | 990.0K | 1.2M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 8.2M | 2.1M | 17.6M | 21.9M | 7.6M |
| Total Non-Current Assets | 1.4B | 1.3B | 2.0B | 1.7B | 1.0B |
| Total Assets | 4.1B | 4.0B | 3.8B | 3.1B | 2.9B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 428.0M | 241.4M | 204.5M | 137.9M | 293.0M |
| Short-term Debt | 45.8M | 724.9M | 831.8M | 577.9M | 620.9M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 6.3M | 5.1M | 3.5M | 9.3M | 7.0M |
| Total Current Liabilities | 593.1M | 1.1B | 1.1B | 782.6M | 967.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | - | - | - | 0 | 0 |
| Deferred Tax Liabilities | 63.1M | 49.8M | 44.2M | 45.8M | 44.4M |
| Other Non-Current Liabilities | 1.8M | 1.2M | 1.3M | 1.1M | 1.8M |
| Total Non-Current Liabilities | 118.1M | 100.0M | 86.6M | 77.6M | 73.6M |
| Total Liabilities | 711.2M | 1.2B | 1.2B | 860.2M | 1.0B |
| Equity | |||||
| Common Stock | 940.0M | 940.0M | 940.0M | 862.5M | 790.0M |
| Retained Earnings | 1.5B | 1.0B | 793.6M | 621.1M | 423.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 3.4B | 2.9B | 2.6B | 2.2B | 1.9B |
| Key Metrics | |||||
| Total Debt | 45.8M | 724.9M | 831.8M | 577.9M | 620.9M |
| Working Capital | 2.1B | 1.7B | 685.3M | 615.4M | 931.4M |
Balance Sheet Composition
Syncom Formulations Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 655.1M | 339.8M | 265.6M | 261.5M | 406.7M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -353.4M | -330.8M | -86.9M | 174.3M | -385.7M |
| Operating Cash Flow | 144.6M | -72.6M | 73.2M | 338.3M | -38.8M |
| Investing Activities | |||||
| Capital Expenditures | -99.6M | -81.4M | -206.3M | -113.1M | -26.6M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | 0 |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | 56.3M | 62.3M | -64.6M | -16.9M | 31.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | -28.2M | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -670.4M | -100.8M | 381.3M | 96.5M | 722.3M |
| Free Cash Flow | 134.8M | -140.9M | -101.1M | 50.2M | -47.2M |
| Net Change in Cash | -469.6M | -111.1M | 389.9M | 417.9M | 714.7M |
Cash Flow Trend
Syncom Formulations Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
18.96
Price to Book
3.37
Price to Sales
2.59
PEG Ratio
0.29
Profitability Ratios
Profit Margin
13.72%
Operating Margin
17.24%
Return on Equity
14.45%
Return on Assets
11.96%
Financial Health
Current Ratio
4.68
Debt to Equity
0.18
Beta
0.67
Per Share Data
EPS (TTM)
₹0.73
Book Value per Share
₹4.10
Revenue per Share
₹5.08
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SYNCOMF | 13.0B | 18.96 | 3.37 | 14.45% | 13.72% | 0.18 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





